Year in Review
Year ended March 2025
Key Figures
- Net Sales
- ¥1,154.0billion
- 4.4%
- Operating Income
- ¥84.7billion
- 0.5%
- Operating Income Ratio
- 7.3%
- 0.3percentage points
- ROE
- 6.8%
- 0.1percentage points
- Capital Expenditures
- ¥56.6billion
- R&D Expenses
- ¥38.8billion
Breakdown by Segment
- Food
- Pharmaceuticals
Net Sales
Operating Income
Business Performance Analysis
Food
- Net Sales
- ¥925.5billion
- 2.8%
- Operating Income
- ¥64.6billion
- 0.5%
- Income Analysis(Billions of yen)
-
Pharmaceuticals
- Net Sales
- ¥229.6billion
- 11.4%
- Operating Income
- ¥24.7billion
- 8.9%
- Income Analysis(Billions of yen)
-
Capital Expenditures
- Food
- Pharmaceuticals
Food
¥40.6billion
Pharmaceuticals
¥15.6billion
Cash Dividends per Share / Dividend Payout Ratio
- Cash Dividends per Share
Dividend Payout Ratio
Future Prospects
This is our Medium-term Business Plan,
FYE 3/2024 through FYE 3/2026.
| FYE3/2024 Results |
FYE3/2025 Results |
FYE3/2026 Targets (Initial plan) |
||
|---|---|---|---|---|
| Net sales | ¥1,105.4 biliion | ¥1,154.0 biliion | ¥1,195.0 biliion | |
| Operating income | ¥84.3 billion | ¥84.7 billion | ¥91.0 billion | |
| Operating income ratio | 7.6% | 7.3% | 7.6% | |
| ROE | 6.9% | 6.8% | 7.0% | |
| as of May 9, 2025 |